Replies to post #231238 on Innovation Pharmaceuticals Inc (IPIX)

[Snowy_Owl]

I'm thinking it's because they haven't been voted "PRO" by some anonymous group.

"Please justify, with examples, your above noted accusation."

[scottsmith]

"Again, I expect no response from you."

Why? I respond to everyone.

You are clearly new to biotech investing if you think ipix has an impressive board. There is a huge difference between being qualified in your field vs. being qualified to sit on a Board that has the ambition to be the next Regeneron.

Lastly, and most importantly, do you realize that Leo goes to the same synagogue as two out of the three board members we are talking about? Gee, quite impressive. Leo searched far and wide for the most qualified board memebrs.

https://pdf.brsonline.org/JounralOnlineBook.pdf

P.S.

To the poster that PM'd me. Great minds think a like because I had looked up that information about 10 minutes ago to confirm what I remembered from years ago. And I also wonder where ol' Leo dug up Mark from.

[MinnieM]

They are far from lightweights....

Research published with Schechter BA on pubmed:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Schechter%20BA%5BAuthor%5D&cauthor=true&cauthor_uid=20845001

Research published with Spektor Z on pubmed:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Zorik+Spektor





In Reply to 'kfcyahoo'
"These guys are total lightweights, have little to no experience in biotech, and no connections. They rubber-stamp every decision."

Please justify, with examples, your above noted accusation.

Barry Schechter, M.D., F.A.A.O: "Dr. Schechter has reviewed articles for Cornea, the British Journal of Ophthalmology, and the Journal of the American Academy of Ophthalmology. He has lectured internationally and published on the subjects of treatment of ocular tumors, lens implants and dry eyes. Dr. Schechter has also written a textbook chapter on surgical techniques. Dr. Schechter is involved in clinical research and consults for several ophthalmic pharmaceutical companies. I guess that's no biotech experience by your definition. By your measure, Dr. Stephen Sonis is a light weight as well in OM, correct? If so, why?
Inflamation is associated with many diseases of the eye(s), his addition makes sense to me in that regard.
I expect no response from you.

Zorik Spektor, M.D., F.A.A.P: "Prior to establishing the Center for Pediatric ENT – Head and Neck Surgery in 1995, Dr. Spektor was on the faculty of the University of Connecticut Health Science Center, Hartford Hospital and Newington Children’s Hospital, now known as Connecticut Children’s Hospital. He has lectured and presented extensively in the field of pediatric otolaryngology, and has authored numerous peer-reviewed publications. Dr. Spektor has been a presenter as well as an invited speaker at local, national and international conferences. He continually conducts clinical research studies, which have produced significant advances in the field of otolaryngology and pediatric otolaryngology. During the past decade he has been selected as one of the nation’s top doctors by several independent rating agencies for many consecutive years. Dr. Spektor has served on advisory boards for several medical device and pharmaceutical companies and has been involved in significant advances in the field of otolaryngology and Pediatric Otolaryngology."

Again, no biotech experience?
Again, I expect no response from you.

Mark Tobin:http://printronix.com/about-us/our-team/norm-judd/

I expect no response from you, and must say, I consider you light weight as far as pro's are concerned(and I don''t claim to be a pro- just so you know)

[loanranger]

There was only one reason for the appointment of independent directors at then CTIX and it was in an unsuccessful attempt to secure a NASDAQ listing. At the time there was some question about the independence of the candidates, but as you can see there shouldn't have been:
http://media.corporate-ir.net/media_files/irol/87/87823/corpgov/nasdaq_marketplace_rule_4200.pdf

The CEO could have arranged for the appointment of his poker buddies, the folks who did his lawn or a couple of his fellow Synagogue members (one of whom lives 3 houses away from him). NASDAQ rules don't preclude that. And that's what he did.

Whether the Doctors in question are capable in their fields is relevant and they don't seem to be "lightweights" in that respect, but if they have the ability to provide independent counsel in a public company boardroom without being influenced by the CEO, or just as importantly the appearance of such an influence, is a separate question.
The fact that no rules were broken may not be the best criteria for judging the value and propriety of those appointments.